S. Jarius and B. Wildemann, The history of neuromyelitis optica, Journal of Neuroinflammation, issue.1, p.10, 2013.

A. Verkman and A. Mitra, Structure and function of aquaporin water channels, American Journal of Physiology-Renal Physiology, vol.278, issue.1, pp.13-28, 2000.

A. Verkman, More than just water channels: unexpected cellular roles of aquaporins, Journal of Cell Science, vol.118, issue.15, pp.3225-3232, 2005.

S. Nielsen, A. Nagelhus, E. Amiry-moghaddam, M. , P. Ottersen et al., Specialized Membrane Domains for Water Transport in Glial Cells: High-Resolution Immunogold Cytochemistry of Aquaporin-4 in Rat Brain, The Journal of Neuroscience, vol.17, issue.1, pp.171-180, 1997.

V. Chang and H. Chang, Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder, Neuropathology and Applied Neurobiology, vol.46, issue.3, pp.199-218, 2019.

M. Papadopoulos, G. Manley, S. Krishna, and A. Verkman, Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema, The FASEB Journal, vol.18, issue.11, pp.1291-1293, 2004.

A. Verkman, P. Phuan, N. Asavapanumas, and L. Tradtrantip, Biology of AQP4 and Anti

. Aqp4-antibody, Therapeutic Implications for NMO, Brain Pathology, vol.23, issue.6, pp.684-695, 2013.

S. Saadoun, M. Papadopoulos, H. Watanabe, and A. Verkman, Involvement of aquaporin-4 in astroglial cell migration and glial scar formation, Journal of Cell Science, vol.118, issue.24, pp.5691-5698, 2005.

D. Binder, X. Yao, Z. Zador, T. Sick, A. Verkman et al., Increased seizure duration and slowed potassium kinetics in mice lacking aquaporin-4 water channels, Glia, vol.53, issue.6, pp.631-636, 2006.

L. Li, H. Zhang, M. Varrin-doyer, S. Zamvil, and A. Verkman, Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation, The FASEB Journal, vol.25, issue.5, pp.1556-1566, 2011.

J. Badaut, F. Lasbennes, P. Magistretti, and L. Regli, Aquaporins in Brain: Distribution, Physiology, and Pathophysiology, Journal of Cerebral Blood Flow & Metabolism, vol.22, issue.4, pp.367-378, 2002.

F. Pisani, M. Mastrototaro, A. Rossi, G. Nicchia, C. Tortorella et al.,

, Identification of Two Major Conformational Aquaporin-4 Epitopes for Neuromyelitis Optica Autoantibody Binding, Journal of Biological Chemistry, vol.286, issue.11, pp.9216-9224, 2011.

M. Matiello, J. Schaefer-klein, D. Sun, and B. Weinshenker, Aquaporin 4 Expression and Tissue Susceptibility to Neuromyelitis Optica, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD 13, vol.70, p.1118, 2013.

S. Saadoun and M. Papadopoulos, Role of membrane complement regulators in neuromyelitis optica, Multiple Sclerosis Journal, vol.21, issue.13, pp.1644-1654, 2015.

C. Linington, M. Bradl, H. Lassmann, C. Brunner, and K. Vass, Augmentation of

D. Pham-dinh, M. Mattei, J. Nussbaum, G. Roussel, P. Pontarotti et al.,

, Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex, Proceedings of the National Academy of Sciences, vol.90, issue.17, pp.7990-7994, 1993.

S. Mader, V. Gredler, K. Schanda, K. Rostasy, I. Dujmovic et al., Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders, Journal of Neuroinflammation, vol.8, issue.1, p.184, 2011.

C. Delarasse, D. Gaspera, B. Lu, C. Lachapelle, F. Gelot et al., Complex alternative splicing of the myelin oligodendrocyte glycoprotein gene is unique to human and non-human primates, Journal of Neurochemistry, vol.98, issue.6, pp.1707-1717, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00091116

M. Reindl and P. Waters, Myelin oligodendrocyte glycoprotein antibodies in neurological disease, Nature Reviews Neurology, vol.15, issue.2, pp.89-102, 2018.

T. Johns and C. Bernard, The Structure and Function of Myelin Oligodendrocyte Glycoprotein, Journal of Neurochemistry, vol.72, issue.1, pp.1-9, 1999.

S. Gold, A. Willing, F. Leypoldt, F. Paul, and M. Friese, Sex differences in autoimmune disorders of the central nervous system, Seminars in Immunopathology, vol.41, issue.2, pp.177-188, 2018.

M. Mori, S. Kuwabara, and F. Paul, Worldwide prevalence of neuromyelitis optica spectrum disorders, Neurosurgery & Psychiatry, vol.89, issue.6, pp.555-556, 2018.

N. Asgari, S. Lillevang, H. Skejoe, M. Falah, E. Stenager et al., A population-based study of neuromyelitis optica in Caucasians, Neurology, vol.76, issue.18, pp.1589-1595, 2011.

E. Flanagan, P. Cabre, B. Weinshenker, J. Sauver, D. Jacobson et al.,

, Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum, Annals of Neurology, vol.79, issue.5, pp.775-783, 2016.

M. Etemadifar, Z. Nasr, B. Khalili, M. Taherioun, R. Vosoughi et al.,

, Neuromyelitis Optica in the World: A Systematic Review and Meta-Analysis. Multiple Sclerosis International, vol.2015, pp.1-8, 2015.

S. Jarius, D. Franciotta, F. Paul, K. Ruprecht, R. Bergamaschi et al., Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD 26

, Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance, Journal of Neuroinflammation, vol.7, issue.1, p.52, 2010.

F. Shimizu, K. Schaller, G. Owens, A. Cotleur, D. Kellner et al., Glucoseregulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica, Science Translational Medicine, vol.9, issue.397, p.9111, 2017.

S. Hillebrand, K. Schanda, M. Nigritinou, I. Tsymala, D. Böhm et al., Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat, Acta Neuropathol (Berl), vol.137, 2018.

A. Uzawa, M. Mori, K. Arai, Y. Sato, S. Hayakawa et al., Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6, Multiple Sclerosis Journal, vol.16, issue.12, pp.1443-1452, 2010.

T. Matsushita, T. Tateishi, N. Isobe, T. Yonekawa, R. Yamasaki et al.,

, Characteristic Cerebrospinal Fluid Cytokine/Chemokine Profiles in Neuromyelitis Optica, Relapsing Remitting or Primary Progressive Multiple Sclerosis, PLoS ONE, vol.8, issue.4, p.61835, 2013.

A. Kimura and T. Kishimoto, IL-6: Regulator of Treg/Th17 balance, European Journal of Immunology, vol.40, issue.7, pp.1830-1835, 2010.

J. Lin, X. Li, and J. Xia, Th17 cells in neuromyelitis optica spectrum disorder: a review, International Journal of Neuroscience, vol.126, issue.12, pp.1051-1060, 2016.

N. Chihara, T. Aranami, W. Sato, Y. Miyazaki, S. Miyake et al., Interleukin 6 of the National Academy of Sciences, vol.108, pp.3701-3706, 2011.

J. Ratelade, H. Zhang, S. Saadoun, J. Bennett, M. Papadopoulos et al.,

, Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss, Acta Neuropathologica, vol.123, issue.6, pp.861-872, 2012.

M. Varrin-doyer, C. Spencer, U. Schulze-topphoff, P. Nelson, R. Stroud et al.,

, Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter, Annals of Neurology, vol.72, issue.1, pp.53-64, 2012.

B. Cree, C. Spencer, M. Varrin-doyer, S. Baranzini, and S. Zamvil, Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens, Annals of Neurology, vol.80, issue.3, pp.443-447, 2016.

, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD

S. Hinson, S. Roemer, C. Lucchinetti, J. Fryer, T. Kryzer et al., Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2, Journal of Experimental Medicine, vol.205, issue.11, pp.2473-2481, 2008.

X. Zeng, X. Sun, L. Gao, Y. Fan, J. Ding et al., Aquaporin-4 deficiency down-regulates glutamate uptake and GLT-1 expression in astrocytes, Molecular and Cellular Neuroscience, vol.34, issue.1, pp.34-39, 2007.

S. Hinson, S. Pittock, C. Lucchinetti, S. Roemer, J. Fryer et al., Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica, Neurology, vol.69, issue.24, pp.2221-2231, 2007.

S. Hinson, M. Romero, B. Popescu, C. Lucchinetti, J. Fryer et al., Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes, Proceedings of the National Academy of Sciences, vol.109, issue.4, pp.1245-1250, 2011.

J. Ratelade and A. Verkman, Neuromyelitis optica: Aquaporin-4 based pathogenesis mechanisms and new therapies, The International Journal of Biochemistry & Cell Biology, vol.44, issue.9, pp.1519-1530, 2012.

S. Jarius, F. Aboul-enein, P. Waters, B. Kuenz, A. Hauser et al., Antibody to aquaporin-4 in the long-term course of neuromyelitis optica, Brain, vol.131, issue.11, pp.3072-3080, 2008.

R. Bernard-valnet, R. Liblau, S. Vukusic, and R. Marignier, Neuromyelitis optica: a positive appraisal of seronegative cases, European Journal of Neurology, vol.22, issue.12, pp.1511-83, 2015.

R. Marignier, R. Bernard-valnet, P. Giraudon, N. Collongues, C. Papeix et al.,

, Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity, Neurology, vol.80, issue.24, pp.2194-2200, 2013.

Y. Jiao, J. Fryer, V. Lennon, S. Jenkins, A. Quek et al., , p.4

, IgG serostatus and disability outcome in neuromyelitis optica, Neurology, vol.81, issue.14, pp.1197-1204, 2013.

D. Wingerchuk, W. Hogancamp, P. O'brien, and B. Weinshenker, The clinical course of neuromyelitis optica (Devic's syndrome), Neurology, vol.53, issue.5, pp.1107-1107, 1999.

V. Lennon, D. Wingerchuk, T. Kryzer, S. Pittock, C. Lucchinetti et al., A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis, The Lancet, vol.364, issue.9451, pp.2106-2112, 2004.

P. Waters, S. Pittock, J. Bennett, S. Jarius, B. Weinshenker et al., Evaluation of aquaporin-4 antibody assays, Clinical and Experimental Neuroimmunology, vol.5, issue.3, pp.290-303, 2014.

, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD

D. Wingerchuk, V. Lennon, S. Pittock, C. Lucchinetti, and B. Weinshenker, Revised diagnostic criteria for neuromyelitis optica, Neurology, vol.66, issue.10, pp.1485-1489, 2006.

D. Wingerchuk, B. Banwell, J. Bennett, P. Cabre, W. Carroll et al., International consensus diagnostic criteria for neuromyelitis optica spectrum disorders, Neurology, vol.85, issue.2, pp.177-189, 2015.

S. Hamid, L. Elsone, K. Mutch, T. Solomon, and A. Jacob, The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates, Multiple Sclerosis Journal, vol.23, issue.2, pp.228-233, 2016.

S. Jarius, K. Ruprecht, I. Kleiter, N. Borisow, N. Asgari et al., MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin, Journal of Neuroinflammation, vol.13, issue.1, 2016.

S. Jarius, K. Ruprecht, I. Kleiter, N. Borisow, N. Asgari et al., MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome, Journal of Neuroinflammation, vol.13, issue.1, 2016.

S. Jarius, I. Kleiter, K. Ruprecht, N. Asgari, K. Pitarokoili et al., MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement -frequency, presentation and outcome, Journal of Neuroinflammation, vol.13, issue.1, 2016.

F. Pache, H. Zimmermann, J. Mikolajczak, S. Schumacher, A. Lacheta et al.,

. Mog-igg, Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgGseropositive patients, NMO and related disorders: a multicenter study of 50 patients, vol.4, 2016.

T. Kezuka, K. Tanaka, Y. Matsunaga, D. Sato, T. Takahashi et al., Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders, Neurology, vol.83, issue.5, pp.475-476, 2014.

S. Hamid, D. Whittam, K. Mutch, S. Linaker, T. Solomon et al., What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients, Journal of Neurology, vol.264, issue.10, pp.2088-2094, 2017.

A. Pröbstel, G. Rudolf, K. Dornmair, N. Collongues, J. Chanson et al., Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype, Journal of Neuroinflammation, vol.12, issue.1, 2015.

H. Nakajima, M. Motomura, K. Tanaka, A. Fujikawa, R. Nakata et al., Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD 59, vol.5, pp.7766-007766, 2015.

Y. Yan, Y. Li, Y. Fu, L. Yang, L. Su et al., Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD, Science China Life Sciences, vol.59, issue.12, pp.1270-1281, 2016.

S. Hamid, D. Whittam, M. Saviour, A. Alorainy, K. Mutch et al., Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease, JAMA Neurology, vol.75, issue.1, p.65, 2018.

R. Höftberger, M. Sepulveda, T. Armangue, Y. Blanco, K. Rostásy et al.,

, Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease, Multiple Sclerosis Journal, vol.21, issue.7, pp.866-874, 2014.

R. Deschamps, A. Lecler, C. Lamirel, J. Aboab, A. Gueguen et al., Etiologies of acute demyelinating optic neuritis: an observational study of 110 patients, European Journal of Neurology, vol.24, issue.6, pp.875-879, 2017.

S. Ramanathan, S. Reddel, A. Henderson, J. Parratt, M. Barnett et al., Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis, Journal of Neuroimmunology, vol.275, issue.1-2, pp.23-24, 2014.

A. Cobo-calvo, A. Ruiz, E. Maillart, B. Audoin, H. Zephir et al., Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study, Neurology, vol.90, issue.21, pp.1858-1869, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01919569

D. Biotti, F. Bonneville, E. Tournaire, X. Ayrignac, C. Dallière et al., Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France, Journal of Neurology, vol.264, issue.10, pp.2173-2175, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01745944

J. Chen, E. Flanagan, J. Jitprapaikulsan, A. López-chiriboga, J. Fryer et al.,

, Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome, American Journal of Ophthalmology, vol.195, pp.8-15, 2018.

K. Chalmoukou, H. Alexopoulos, S. Akrivou, P. Stathopoulos, M. Reindl et al.,

, Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis, Neurology -Neuroimmunology Neuroinflammation, vol.2, issue.4, p.131, 2015.

C. Alves-do-rego and N. Collongues, Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes, Revue Neurologique, vol.174, issue.6, pp.458-470, 2018.

R. Wynford-thomas, A. Jacob, and V. Tomassini, Neurological update: MOG antibody disease, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD 70, vol.266, pp.1280-1286, 2018.

H. Lassmann, C. Brunner, M. Bradl, and C. Linington, Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions, Acta Neuropathologica, vol.75, issue.6, pp.566-576, 1988.

R. Weissert, K. De-graaf, M. Storch, S. Barth, C. Linington et al., MHC Class II-Regulated Central Nervous System Autoaggression and T Cell Responses in Peripheral Lymphoid Tissues Are Dissociated in Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis, The Journal of Immunology, vol.166, issue.12, pp.7588-7599, 2001.

S. Mariotto, S. Ferrari, S. Monaco, M. Benedetti, K. Schanda et al., Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibodyassociated syndromes: a multicenter study, Journal of Neurology, vol.264, issue.12, pp.2420-2430, 2017.

S. Mader, T. Kümpfel, and E. Meinl, Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG-and MOG-IgG-associated diseases, Current Opinion in Neurology, vol.33, issue.3, pp.362-371, 2020.

P. Peschl, K. Schanda, B. Zeka, K. Given, D. Böhm et al., Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination, Journal of Neuroinflammation, vol.14, issue.1, 2017.

H. Von-büdingen, F. Mei, A. Greenfield, S. Jahn, Y. Shen et al., The myelin oligodendrocyte glycoprotein directly binds nerve growth factor to modulate central axon circuitry, Journal of Cell Biology, vol.210, issue.6, pp.891-898, 2015.

S. Saadoun, P. Waters, G. Owens, J. Bennett, A. Vincent et al., Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain, Acta Neuropathologica Communications, vol.2, issue.1, 2014.

A. Flach, T. Litke, J. Strauss, M. Haberl, C. Gómez et al.,

, T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease, Proceedings of the National Academy of Sciences, vol.113, issue.12, pp.3323-3328, 2016.

M. Spadaro, L. Gerdes, M. Mayer, B. Ertl-wagner, S. Laurent et al.,

, Histopathology and clinical course of MOG-antibody-associated encephalomyelitis, Annals of Clinical and Translational Neurology, vol.2, issue.3, pp.295-301, 2015.

J. Wang, Z. Jaunmuktane, C. Mummery, S. Brandner, S. Leary et al., Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD, Neurology, vol.87, issue.2, pp.229-231, 2016.

K. Kaneko, D. Sato, I. Nakashima, S. Nishiyama, S. Tanaka et al., Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies, Neurosurgery & Psychiatry, vol.87, issue.11, pp.1257-1259, 2016.

S. Jarius, F. Paul, O. Aktas, N. Asgari, R. Dale et al., MOG encephalomyelitis: international recommendations on diagnosis and antibody testing, Journal of Neuroinflammation, vol.15, issue.1, 2018.

M. Jury?czyk, A. Jacob, K. Fujihara, and J. Palace, Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations, Practical Neurology, vol.19, issue.3, pp.187-195, 2018.

D. Sato, M. Lana-peixoto, K. Fujihara, and J. De-seze, Clinical Spectrum and Treatment

, Neuromyelitis Optica Spectrum Disorders: Evolution and Current Status, Brain Pathology, vol.23, issue.6, pp.647-660, 2013.

S. Kim, M. Go, J. Sung, K. Park, and K. Lee, Painful Tonic Spasm in Neuromyelitis Optica, Archives of Neurology, vol.69, issue.8, 2012.

S. Jarius, K. Ruprecht, B. Wildemann, T. Kuempfel, M. Ringelstein et al.,

, Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients, Journal of Neuroinflammation, vol.9, issue.1, 2012.

E. Benarroch, Circumventricular organs: Receptive and homeostatic functions and clinical implications, Neurology, vol.77, issue.12, pp.1198-1204, 2011.

T. Takahashi, I. Miyazawa, T. Misu, R. Takano, I. Nakashima et al., Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations, Neurosurgery & Psychiatry, vol.79, issue.9, pp.1075-1078, 2008.

L. Kremer, M. Mealy, A. Jacob, I. Nakashima, P. Cabre et al., Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients, Multiple Sclerosis Journal, vol.20, issue.7, pp.843-847, 2013.

B. Dutra, A. Da-rocha, R. Nunes, and A. Maia, Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis, RadioGraphics, vol.38, issue.1, pp.169-193, 2018.

D. Dubey, S. Pittock, K. Krecke, P. Morris, E. Sechi et al., Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody, JAMA Neurology, vol.76, issue.3, p.301, 2019.

L. Grangeon, B. Hébant, M. Guillaume, P. Ahtoy, and R. Lefaucheur, Myelitis with normal spinal cord MRI: don't forget anti-MOG antibodies disease!, Acta Neurologica Belgica, 2020.

E. Sechi, K. Krecke, S. Pittock, D. Dubey, A. Lopez-chiriboga et al.,

, Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies, Multiple Sclerosis Journal, p.135245852090790, 2020.

F. Barkhof, M. Filippi, D. Miller, P. Scheltens, A. Campi et al., Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

, Brain J Neurol, vol.120, pp.2059-69, 1997.

H. Abboud, A. Petrak, M. Mealy, S. Sasidharan, L. Siddique et al., Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange, Multiple Sclerosis Journal, vol.22, issue.2, pp.185-192, 2015.

I. Kleiter, A. Gahlen, N. Borisow, K. Fischer, K. Wernecke et al., Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses, Annals of Neurology, vol.79, issue.2, pp.206-216, 2015.

B. Weinshenker, P. O'brien, T. Petterson, J. Noseworthy, C. Lucchinetti et al.,

, A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease, Annals of Neurology, vol.46, issue.6, pp.878-886, 1999.

M. Bonnan, R. Valentino, S. Olindo, H. Mehdaoui, D. Smadja et al., Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder, Multiple Sclerosis Journal, vol.15, issue.4, pp.487-492, 2009.

C. Osman, R. Jennings, K. El-ghariani, and A. Pinto, Plasma exchange in neurological disease

, Practical Neurology, vol.20, issue.2, pp.92-99, 2019.

, Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for

, Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders. Case Medical Research, ClinicalTrials.gov, 2019.

M. Bonnan, R. Valentino, S. Debeugny, H. Merle, J. Fergé et al., Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders, Neurosurgery & Psychiatry, vol.89, issue.4, pp.346-351, 2017.

M. Bonnan and P. Cabre, Plasma Exchange in Severe Attacks of Neuromyelitis Optica

, Multiple Sclerosis International, vol.2012, pp.1-9, 2012.

I. Cortese, V. Chaudhry, Y. So, F. Cantor, D. Cornblath et al., Evidence-based guideline update: Plasmapheresis in neurologic disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, vol.76, pp.294-300, 2011.

, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD

J. Schwartz, A. Padmanabhan, N. Aqui, R. Balogun, L. Connelly-smith et al.,

, Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue, Journal of Clinical Apheresis, vol.31, issue.3, pp.149-338, 2016.

L. Elsone, J. Panicker, K. Mutch, M. Boggild, R. Appleton et al., Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients, Multiple Sclerosis Journal, vol.20, issue.4, pp.501-504, 2013.

M. Levy and M. Mealy, Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica, Neurology -Neuroimmunology Neuroinflammation, vol.1, issue.1, p.5, 2014.

D. Kimbrough, K. Fujihara, A. Jacob, M. Lana-peixoto, I. Leite et al., Treatment of neuromyelitis optica: Review and recommendations. Multiple Sclerosis and Related Disorders, vol.1, pp.180-187, 2012.

J. Stellmann, M. Krumbholz, T. Friede, A. Gahlen, N. Borisow et al.,

, Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response, Neurosurgery & Psychiatry, vol.88, issue.8, pp.639-647, 2017.

S. Watanabe, T. Misu, I. Miyazawa, I. Nakashima, Y. Shiga et al., Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis, Multiple Sclerosis Journal, vol.13, issue.8, pp.968-974, 2007.

S. Ramanathan, S. Mohammad, E. Tantsis, T. Nguyen, V. Merheb et al., Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination, Neurosurgery & Psychiatry, vol.89, issue.2, pp.127-137, 2017.

S. Viswanathan, A. Wong, A. Quek, and Y. N. , Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica, Journal of Neuroimmunology, vol.282, pp.92-96, 2015.

C. Costanzi, M. Matiello, C. Lucchinetti, B. Weinshenker, S. Pittock et al.,

, Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica, Neurology, vol.77, issue.7, pp.659-666, 2011.

Z. Nikoo, S. Badihian, V. Shaygannejad, N. Asgari, and F. Ashtari, Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial, Journal of Neurology, vol.264, issue.9, pp.2003-2009, 2017.

A. Cobo-calvo, M. Sepúlveda, F. Rollot, T. Armangué, A. Ruiz et al., Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease, Journal of Neuroinflammation, vol.16, issue.1, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02180590

, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD

A. Jacob, M. Matiello, B. Weinshenker, D. Wingerchuk, C. Lucchinetti et al., Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: retrospective analysis of 24 patients, Archives of Neurology, vol.66, issue.9, 2009.

H. Chen, Y. Zhang, Z. Shi, H. Feng, S. Yao et al., The Efficacy and Tolerability

, Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China, Clinical Neuropharmacology, vol.39, issue.2, pp.81-87, 2016.

Y. Yang, C. Wang, B. Wang, Z. Zeng, and S. Guo, Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder, Journal of the Neurological Sciences, vol.385, pp.192-197, 2018.

H. Chen, W. Qiu, Q. Zhang, J. Wang, Z. Shi et al., Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder, European Journal of Neurology, vol.24, issue.1, pp.219-226, 2016.

A. Montcuquet, N. Collongues, C. Papeix, H. Zephir, B. Audoin et al., Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders, Multiple Sclerosis Journal, vol.23, issue.10, pp.1377-1384, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01798528

M. Mealy, S. Kim, F. Schmidt, R. López, J. Arango et al., Aquaporin-4 Sclerosis Journal, vol.24, issue.13, pp.1737-1742, 2017.

B. Cree, S. Lamb, K. Morgan, A. Chen, E. Waubant et al., An open label study of the effects of rituximab in neuromyelitis optica, Neurology, vol.64, issue.7, pp.1270-1272, 2005.

M. Mealy, D. Wingerchuk, J. Palace, B. Greenberg, and M. Levy, Comparison of Relapse and Treatment Failure Rates Among Patients With Neuromyelitis Optica: multicenter study of treatment efficacy, JAMA Neurology, vol.71, issue.3, p.324, 2014.

H. Zéphir, R. Bernard-valnet, C. Lebrun, O. Outteryck, B. Audoin et al.,

, Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability, Journal of Neurology, vol.262, issue.10, pp.2329-2335, 2015.

P. Cabre, M. Mejdoubi, S. Jeannin, H. Merle, Y. Plumelle et al., Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study, Journal of Neurology, vol.265, issue.4, pp.917-925, 2018.

R. Ramanathan, K. Malhotra, and T. Scott, Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate, BMC Neurology, vol.14, issue.1, 2014.

, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD

J. Kitley, L. Elsone, J. George, P. Waters, M. Woodhall et al., Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4

, Neurosurgery & Psychiatry, vol.84, issue.8, pp.918-921, 2013.

G. Tackley, F. O'brien, J. Rocha, M. Woodhall, P. Waters et al.,

, Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment. Multiple Sclerosis and Related Disorders, vol.7, pp.21-25, 2016.

P. Cabre, S. Olindo, R. Marignier, S. Jeannin, H. Merle et al., Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study, Neurosurgery & Psychiatry, vol.84, issue.5, pp.511-516, 2012.

M. Araki, T. Matsuoka, K. Miyamoto, S. Kusunoki, T. Okamoto et al., Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study, Neurology, vol.82, issue.15, pp.1302-1306, 2014.

M. Ringelstein, I. Ayzenberg, J. Harmel, A. Lauenstein, E. Lensch et al., Longterm Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder, JAMA Neurology, vol.72, issue.7, p.756, 2015.

, Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders

. Clinicaltrials and . Gov,

B. Cree, J. Bennett, H. Kim, B. Weinshenker, S. Pittock et al., Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. The Lancet, vol.394, pp.1352-1363, 2019.

S. Pittock, V. Lennon, A. Mckeon, J. Mandrekar, B. Weinshenker et al.,

, Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an openlabel pilot study. The Lancet Neurology, vol.12, pp.554-562, 2013.

S. Pittock, A. Berthele, K. Fujihara, H. Kim, M. Levy et al., Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder, New England Journal of Medicine, vol.381, issue.7, pp.614-625, 2019.

T. Yamamura, I. Kleiter, K. Fujihara, J. Palace, B. Greenberg et al., Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder, New England Journal of Medicine, vol.381, issue.22, pp.2114-2124, 2019.

A. Traboulsee, B. Greenberg, J. Bennett, L. Szczechowski, E. Fox et al.,

, Efficacy and safety of satralizumab monotherapy for relapse prevention in neuromyelitis optica spectrum disorder (NMOSD): Results from SAkuraStar, a double-blind placebo-controlled phase 3 clinical study, Journal of the Neurological Sciences, vol.405, p.171, 2019.

J. Bennett, B. Greenberg, A. Traboulsee, L. Szczechowski, E. Fox et al., Efficacy of satralizumab as monotherapy in pre-specified subgroups of SAkuraStar, a doubleblind placebo-controlled phase 3 clinical study in patients with neuromyelitis optica spectrum disorder (NMOSD), Journal of the Neurological Sciences, vol.405, p.172, 2019.

N. Collongues, E. Ayme-dietrich, L. Monassier, and J. De-seze, Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options, Drugs, vol.79, issue.2, pp.125-142, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02554078

H. Merle, S. Olindo, M. Bonnan, A. Donnio, R. Richer et al., Natural History of the Visual Impairment of Relapsing Neuromyelitis Optica, Ophthalmology, vol.114, issue.4, p.810, 2007.

P. Cabre, A. Gonzalez-quevedo, M. Bonnan, A. Saiz, S. Olindo et al., Relapsing neuromyelitis optica: long term history and clinical predictors of death, Neurosurgery & Psychiatry, vol.80, issue.10, pp.1162-1164, 2009.

S. Watanabe, I. Nakashima, T. Misu, I. Miyazawa, Y. Shiga et al., Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica, Multiple Sclerosis Journal, vol.13, issue.1, pp.128-132, 2007.

I. Kleiter, A. Gahlen, N. Borisow, K. Fischer, K. Wernecke et al., Apheresis therapies for NMOSD attacks, Neurology -Neuroimmunology Neuroinflammation

H. Stiebel-kalish, M. Hellmann, M. Mimouni, F. Paul, O. Bialer et al., Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis, Neurology -Neuroimmunology Neuroinflammation, 2019.

J. Kurtzke, Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-1444, 1983.

, Facteurs pronostiques de la première attaque dans les NMOSD et les MOGAD